Literature DB >> 7007440

Insulin resistance in uremia.

R A DeFronzo, A Alvestrand, D Smith, R Hendler, E Hendler, J Wahren.   

Abstract

Tissue sensitivity to insulin was examined with the euglycemic insulin clamp technique in 17 chronically uremic and 36 control subjects. The plasma insulin concentration was raised by approximately 100 microU/ml and the plasma glucose concentration was maintained at the basal level with a variable glucose infusion. Under these steady-state conditions of euglycemia, the glucose infusion rate is a measure of the amount of glucose taken up by the entire body. In uremic subjects insulin-mediated glucose metabolism was reduced by 47% compared with controls (3.71 +/- 0.20 vs. 7.38 +/- 0.26 mg/kg . min; P less than 0.001). Basal hepatic glucose production (measured with [3H]-3-glucose) was normal in uremic subjects (2.17 +/- 0.04 mg/kg . min) and suppressed normally by 94 +/- 2% following insulin administration. In six uremic and six control subjects, net splanchnic glucose balance was also measured directly by the hepatic venous catheterization technique. In the postabsorptive state splanchnic glucose production was similar in uremics (1.57 +/- 0.03 mg/kg . min) and controls (1.79 +/- 0.20 mg/kg . min). After 90 min of sustained hyperinsulinemia, splanchnic glucose balance reverted to a net uptake which was similar in uremics (0.42 +/- 0.11 mg/kg . min) and controls (0.53 +/- 0.12 mg/kg . min). In contrast, glucose uptake by the leg was reduced by 60% in the uremic group (21 +/- 1 vs. 52 +/- 8 mumol/min . kg of leg wt; P less than 0.005) and this decrease closely paralleled the decrease in total glucose metabolism by the entire body. These results indicate that: (a) suppression of hepatic glucose production by physiologic hyperinsulinemia is not impaired by uremia, (b) insulin-mediated glucose uptake by the liver is normal in uremic subjects, and (c) tissue insensitivity to insulin is the primary cause of insulin resistance in uremia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7007440      PMCID: PMC370600          DOI: 10.1172/JCI110067

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Carbohydrate metabolism in uremia: inhibition of phosphate release.

Authors:  B D Cohen; H I Horowitz
Journal:  Am J Clin Nutr       Date:  1968-05       Impact factor: 7.045

2.  Carbohydrate metabolism in uremia.

Authors:  E S Horton; C Johnson; H E Lebovitz
Journal:  Ann Intern Med       Date:  1968-01       Impact factor: 25.391

3.  Carbohydrate metabolism in renal disease.

Authors:  I M Spitz; A H Rubenstein; I Bersohn; C Abrahams; C Lowy
Journal:  Q J Med       Date:  1970-04

4.  Uremia and insulin response.

Authors:  F B Westervelt
Journal:  Arch Intern Med       Date:  1970-11

5.  Insulin effect in uremia.

Authors:  F B Westervelt
Journal:  J Lab Clin Med       Date:  1969-07

6.  Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method.

Authors:  J S Cowan; G Hetenyi
Journal:  Metabolism       Date:  1971-04       Impact factor: 8.694

7.  Leg blood flow during exercise in man.

Authors:  L Jorfeldt; J Wahren
Journal:  Clin Sci       Date:  1971-11       Impact factor: 6.124

8.  Azotemia and glucose intolerance.

Authors:  J M Cerletty; N H Engbring
Journal:  Ann Intern Med       Date:  1967-06       Impact factor: 25.391

9.  Effect of chronic renal failure and hemodialysis on carbohydrate metabolism.

Authors:  C L Hampers; J S Soeldner; P B Doak; J P Merrill
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

10.  The renal handling of insulin.

Authors:  M J Chamberlain; L Stimmler
Journal:  J Clin Invest       Date:  1967-06       Impact factor: 14.808

View more
  102 in total

1.  Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD.

Authors:  Georg Biesenbach; Gert Bodlaj; Stephan Ebner; Peter Biesenbach; Herwig Pieringer
Journal:  Int Urol Nephrol       Date:  2010-07-20       Impact factor: 2.370

2.  Defective glucose utilization in patients with functioning beta-cell tumors persists after tumor excision.

Authors:  G S McGee; M M Kulaylat; N N Abumrad
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

3.  Insulin resistance and left ventricular mass in non-diabetic hemodialysis patients.

Authors:  Sebnem Karakan; Siren Sezer; F Nurhan Ozdemir Acar
Journal:  Curr Ther Res Clin Exp       Date:  2012-12

Review 4.  Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field.

Authors:  Natasha Dave; Jiao Wu; Sandhya Thomas
Journal:  Curr Diab Rep       Date:  2018-06-08       Impact factor: 4.810

5.  Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.

Authors:  R A DeFronzo; R Gunnarsson; O Björkman; M Olsson; J Wahren
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

Review 6.  Carbohydrate metabolism in uremia.

Authors:  R H Mak
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

7.  Thermic effect of glucose in man. Obligatory and facultative thermogenesis.

Authors:  K J Acheson; E Ravussin; J Wahren; E Jéquier
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

8.  Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion.

Authors:  B Ludvik; M Clodi; A Kautzky-Willer; M Schuller; H Graf; E Hartter; G Pacini; R Prager
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 9.  An overview of renal metabolomics.

Authors:  Sahir Kalim; Eugene P Rhee
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

10.  Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine.

Authors:  M Stumvoll; U Chintalapudi; G Perriello; S Welle; O Gutierrez; J Gerich
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.